Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study).

ABSTRACT:

Background

Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.

Objective

To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart^® and assess injection-site reactions and treatment satisfaction.

Methods

This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13-23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.

Results

Sixty patients were recruited (mean age 43

SUBMITTER: Pedersen ED 

PROVIDER: S-EPMC5916453 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature